timolumab   

GtoPdb Ligand ID: 9097

Synonyms: 8c10 | BTT-1023 | BTT1023 | r8c10 | SI-3106 | SI-636
Compound class: Antibody
Comment: Tmolumab is a fully human anti-AOC3 (amine oxidase copper containing 3, VAP1) monoclonal antibody being investigated for its immunomodulatory action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US7897149, in particular with the recombinant fully human antibody BTT-1023 named therein [1].
No information available.
Summary of Clinical Use
Timolumab (with research code BTT1023) is being evaluated in Phase II clinical trial NCT02239211, for its potential to treat patients with primary sclerosing cholangitis, an uncommon and progressive disease of the bile ducts characterised by inflammation and obliterative fibrosis. Phase I studies for RA and psoriasis have been completed (2010/11).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02239211 A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Phase 2 Interventional University of Birmingham